Updated on 4 August 2014
Taiwan moving towards trillion mark
Dr Johnsee Lee, BioTaiwan Organizing Committee Chairman explained that the market value of the local industry has reached 900 B TWD (30 B USD) and will soon approach its first trillion TWD as Taiwan slowly becomes an integral part of the global biopharma industry chain. "The government's initiatives to support Taiwan's biotech development and innovation are critical for the strong growth momentum."
Officials explained at one of the public seminars held around a lunch gathering, "There are notable increases in late-stage clinical trials, company investment in R&D and manufacturing capacity, international partnerships and market expansion. The licensing deals have once again exceeded the past."
Further, with the addition of big players like Quintiles, Johnson & Johnson, DePuySynthes, BioCentury, King biotechnology company, Zhejiang Medicine Company, Qisda Corporation, Shanghai CITIC - alongside the Industrial Development Bureau, Ministry of Economic Affairs Secretary and China Biotechnology Development Director of the Centre best business opportunities in the biotechnology industry remained the main focus.
Asia's bio-business economy
For the Asian participants, the BioBusiness Asia conference, organized by state-sponsored Industrial Technology Research Institute was the highlight of the first two days of the event. This special conference had representatives from some major international firms, who for the first time, spilt out the real tricks of the trade.
The event's keynote speaker, Mr David Flores, the Co-Founder and President & CEO of BioCentury Publications along with the fiery duo on the panel - Mr Carl Firth, CEO of Singapore's ASLAN Pharmaceuticals and Mr Ross Horsburgh, senior vice president of research outfit Quintiles broke down the trends that are currently in the limelight. They further revealed each of their development strategies.